EISAI CO

The National Institute for Health and Care Excellence (NICE) has refused to recommend lecanemab and donanemab for NHS use, denying access to over 70,000 eligible patients in England unless they can afford private treatment costing £60,000-80,000 annually.

Gyre Therapeutics has successfully dosed the first volunteer in a Phase 1 clinical trial evaluating F230, a novel endothelin A receptor antagonist, for treating pulmonary arterial hypertension in China.

SEED Therapeutics appointed Dr. Bill Desmarais as Chief Financial Officer and Chief Business Officer to strengthen strategic partnerships and advance clinical trials.

Eisai has successfully defended its Lenvima patent in a US court case, securing protection against generic competition until 2036.

Eisai and Merck successfully defended a key patent for cancer drug Lenvima against Shilpa Medicare's challenge, with a federal judge ruling the patent describes the invention clearly and in sufficient detail.

Eisai's Phase Ib trial of E7386 in combination with lenvatinib demonstrated a 30% overall response rate in advanced endometrial cancer patients who progressed after platinum-based chemotherapy and immunotherapy.

Eisai will showcase long-term follow-up data from the Phase 3 LEAP-002 study evaluating lenvatinib plus pembrolizumab versus lenvatinib monotherapy in first-line unresectable hepatocellular carcinoma treatment.

Japan's Ministry of Health has lifted the all-case surveillance requirement for Eisai's anticancer agent Remitoro after reviewing safety data from 111 patients and efficacy data from 85 patients with T-cell lymphoma.

FidoCure and Stanford researchers have published groundbreaking findings showing targeted therapies significantly improve survival rates in dogs with splenic hemangiosarcoma, the deadliest canine cancer.

Algernon Pharmaceuticals has entered into agreements to acquire NoBrainer Imaging Centers, gaining exclusive rights to establish Alzheimer's diagnostic and treatment clinics across Canada and select U.S. markets.